FLAMEL'S LOSSES SOAR AS IT GEARS UP FOR COREG

A A

As it prepares for the launch of GlaxoSmithKline's beta-blocker Coreg (carvedilol) with a controlled release formulation, drug delivery company Flamel saw its bottom line, in the absence of new partners, shift deep into the red in the first quarter of 2006.

DrugResearcher.com (http://www.drugresearcher.com/news/ng.asp?n=67842-flammel-coreg-glaxosmithkline-micropump-medusa)